Within the heart, GHRH agonists can activate cardiac repair after experimental myocardial infarction in rats, suggesting the existence of a potential signaling pathway based on GHRH in the heart [304], clearly demonstrating that peptides, as with any other pharmacological functional molecules, can have both beneficial and toxic effects depending on the prescription and the dose administrated. The gene discussed is GHRH; the disease is myocardial infarction.